Guggenheim Capital’s AnaptysBio ANAB Stock Holding History

Guggenheim Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-30,203	Closed	-$3.01M	–	2170
2018 Q3	$3.01M	Sell	30,203 -1,906	-6%	-$158K	0.02%	1017
2018 Q2	$2.28M	Buy	32,109 +7,119	+28%	+$597K	0.02%	1174
2018 Q1	$2.6M	Buy	+24,990	New	+$2.82M	0.01%	1441

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Guggenheim Capital's ANAB Position: Q4 2018 in Review

Guggenheim Capital sold out of AnaptysBio (ANAB) in Q4 2018, closing a stake of 30,203 shares — an estimated $3.01M sold.

Guggenheim Capital first reported a position in ANAB in Q1 2018 and held it in 3 quarters. The position peaked at $3.01M in Q3 2018. 121 funds tracked by Wall St. Rank hold ANAB as of Q4 2018.

Guggenheim Capital reported no remaining AnaptysBio position as of Q4 2018 after selling out during the quarter.
Guggenheim Capital sold 30,203 AnaptysBio shares in Q4 2018, an estimated $3.01M.
Guggenheim Capital first reported a position in AnaptysBio in Q1 2018 and held it in 3 quarters.
Guggenheim Capital's AnaptysBio position peaked at $3.01M in Q3 2018.
121 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2018.

Based on Guggenheim Capital's 13F filing for Q4 2018, filed 14 Feb 2019.